Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Immunotherapy

FDA Approves First Gene Therapy to U.S.; Commissioner Gottlieb Says ‘A New Frontier in Medical Innovation’

Washington, DC, September 1, 2017 — The Food and Drug Administration (FDA) issued a historic action on August 30 making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).

FDA Commissioner Scott Gottlieb, M.D., said, “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer.” Continue reading

Rutgers Cancer Institute Reports Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer

Dr. Janice M. Mehnert

New Brunswick, NJ, August 18, 2017 — The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease.

That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world. The work appears in the current online edition of the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.72.5069).

Janice M. Mehnert, MD, director of the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute, and senior director on the work said, “Immunotherapy drugs put the body’s natural defenses bak to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells.” Continue reading

Rutgers Cancer Institute of New Jersey Investigators Receive $450K in Fellowship Grants

New Brunswick, NJ, July 27, 2017 — Rutgers Cancer Institute of New Jersey investigators have received $450,000 in funding to support research projects in immunotherapy and basic science research that could impact pancreatic, breast and other cancers.

The Pre- and Post-Doctoral Fellowship Grants were awarded by the New Jersey Commission on Cancer Research (NJCCR).

Eileen White, Ph.D., Rutgers Cancer Institute Deputy Director, Chief Scientific Officer and Associate Director for Basic Science, said, “As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute is dedicated to treatment, prevention, education and research.” Continue reading